» Articles » PMID: 34244365

Dynamic Change of Endocannabinoid Signaling in the Medial Prefrontal Cortex Controls the Development of Depression After Neuropathic Pain

Overview
Journal J Neurosci
Specialty Neurology
Date 2021 Jul 10
PMID 34244365
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Many patients with chronic pain conditions suffer from depression. The mechanisms underlying pain-induced depression are still unclear. There are critical links of medial prefrontal cortex (mPFC) synaptic function to depression, with signaling through the endocannabinoid (eCB) system as an important contributor. We hypothesized that afferent noxious inputs after injury compromise activity-dependent eCB signaling in the mPFC, resulting in depression. Depression-like behaviors were tested in male and female rats with traumatic neuropathy [spared nerve injury (SNI)], and neuronal activity in the mPFC was monitored using the immediate early gene c- and electrophysiological recordings. mPFC eCB Concentrations were determined using mass spectrometry, and behavioral and electrophysiological experiments were used to evaluate the role of alterations in eCB signaling in depression after pain. SNI-induced pain induced the development of depression phenotypes in both male and female rats. Pyramidal neurons in mPFC showed increased excitability followed by reduced excitability in the onset and prolonged phases of pain, respectively. Concentrations of the eCBs, 2-arachidonoylglycerol (2-AG) in the mPFC, were elevated initially after SNI, and our results indicate that this resulted in a loss of CB1R function on GABAergic interneurons in the mPFC. These data suggest that excessive release of 2-AG as a result of noxious stimuli triggers use-dependent loss of function of eCB signaling leading to excessive GABA release in the mPFC, with the final result being behavioral depression. Pain has both somatosensory and affective components, so the complexity of mechanisms underlying chronic pain is best represented by a biopsychosocial model that includes widespread CNS dysfunction. Many patients with chronic pain conditions develop depression. The mechanism by which pain causes depression is unclear. Although manipulation of the eCB signaling system as an avenue for providing analgesia per se has not shown much promise in previous studies. An important limitation of past research has been inadequate consideration of the dynamic nature of the connection between pain and depression as they develop. Here, we show that activity-dependent synthesis of eCBs during the initial onset of persistent pain is the critical link leading to depression when pain is persistent.

Citing Articles

Improvement in the Cognitive Function in Chronic Pain: Therapeutic Potential of the Endocannabinoid System.

Karimi-Haghighi S, Shaygan M Mol Neurobiol. 2025; .

PMID: 40059255 DOI: 10.1007/s12035-025-04814-8.


The endocannabinoid system in the brain undergoes long-lasting changes following neuropathic pain.

Zhang M, Wang T, Meng F, Jiang M, Wu S, Xu H iScience. 2024; 27(12):111409.

PMID: 39717086 PMC: 11664153. DOI: 10.1016/j.isci.2024.111409.


Endocannabinoid interference blocks post-global cerebral ischemia depression through prefrontal cortico-amygdala projections.

Tu Z, Ma Y, Shang H, Zhao S, Xue B, Qu Y Neuropsychopharmacology. 2024; .

PMID: 39582030 DOI: 10.1038/s41386-024-02029-4.


Inhibition of CB1R in the Hypothalamic Paraventricular Nucleus Ameliorates Hypertension Through Wnt/β-Catenin/RAS Pathway.

Gao H, Yang Y, Tian H, Fu L, Liu K, Jia X Cardiovasc Toxicol. 2024; 25(1):9-23.

PMID: 39467886 DOI: 10.1007/s12012-024-09938-2.


Excessive alcohol intake produces persistent mechanical allodynia and dysregulates the endocannabinoid system in the lumbar dorsal root ganglia of genetically-selected Marchigian Sardinian alcohol-preferring rats.

Borgonetti V, Vozella V, Ware T, Cruz B, Bullard R, Cravatt B Pharmacol Res. 2024; 209:107462.

PMID: 39396766 PMC: 11834946. DOI: 10.1016/j.phrs.2024.107462.


References
1.
Li X, Hu L . The Role of Stress Regulation on Neural Plasticity in Pain Chronification. Neural Plast. 2017; 2016:6402942. PMC: 5178373. DOI: 10.1155/2016/6402942. View

2.
Araque A, Castillo P, Manzoni O, Tonini R . Synaptic functions of endocannabinoid signaling in health and disease. Neuropharmacology. 2017; 124:13-24. PMC: 5662005. DOI: 10.1016/j.neuropharm.2017.06.017. View

3.
Patel S, Rademacher D, Hillard C . Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther. 2003; 306(3):880-8. DOI: 10.1124/jpet.103.054270. View

4.
Hill E, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P . Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol. 2007; 97(4):2580-9. DOI: 10.1152/jn.00603.2006. View

5.
Bodor A, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N . Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. 2005; 25(29):6845-56. PMC: 6725346. DOI: 10.1523/JNEUROSCI.0442-05.2005. View